-
MabPharm’s CMAB007 Receives NMPA Approval for IgE-Mediated Asthma Treatment
•
Taizhou-based monoclonal antibody (mAb) biosimliars specialist MabPharm Ltd (HKG: 2181) has announced that it has attained market approval from the National Medical Products Administration (NMPA) for its CMAB007, a biosimilar version of Roche/Genentech’s anti-IgE dermatology and asthma therapy omalizumab (trade name: Xolair). This approval marks the first home-grown therapeutic biologic…
-
Alibaba Health Reports 30.1% Revenue Growth in 2022 Financial Report
•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the year ended March 31, 2023, recording RMB 26.763 billion (USD 3.8 billion) in revenue, marking a 30.1% year-on-year (YOY) increase. The company’s net profit for the year reached RMB 534 million (USD 76 million), a…
-
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
•
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), has been officially launched in the Chinese market. The drug received marketing approval in China in February 2023 and is now available for the treatment of unresectable or metastatic HER2 positive…
-
BeiGene’s Tislelizumab Approved in China for First-Line Esophageal Squamous Cell Carcinoma
•
BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has been approved in China as a first-line therapy for non-resectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). This approval comes as part of a combination therapy including chemotherapy regimens of paclitaxel and platinum or…
-
Bayer’s Copanlisib (Aliqopa) Approved by NMPA for Recurrent Follicular Lymphoma
•
The National Medical Products Administration (NMPA) has indicated on its website that Bayer’s (ETR: BAYN) copanlisib (trade name: Aliqopa) has been granted approval as a monotherapy treatment for recurrent or refractory follicular lymphoma (FL) in China. This approval is specifically for patients who have failed at least two previous systemic…
-
Azenta Life Sciences and Vazyme Biotech Form Global Partnership for Comprehensive Services
•
Azenta Life Sciences (NASDAQ: AZTA) has entered into a global partnership with China-based Vazyme Biotech Co., Ltd (SHA: 688105) to enhance their joint “one-stop” service process. This collaboration covers a wide range of fields, including high-throughput sequencing, automated database building, raw material supply, experimental consumables, and sample storage. Financial details…
-
3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients
•
China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a Phase III clinical study for its thrombopoietin, which is being assessed for the treatment of thrombocytopenia in patients with chronic liver disease who are planned for invasive surgery. Background of 3SBio’s Thrombopoietin (TPIAO)Developed in-house, 3SBio’s…
-
Shanghai Junshi Biosciences’ Tuoyi Combo for Triple Negative Breast Cancer Accepted for Review
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the regulatory authorities have accepted for review another indication approval filing for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with paclitaxel (albumin bound) for the treatment of PD-L1 positive (CPS ≥ 1) primary metastatic or recurrent metastatic…
